228760 — Genomictree Income Statement
0.000.00%
Last trade - 00:00
- KR₩500bn
- KR₩416bn
- KR₩3bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 282 | 1,239 | 5,140 | 29,866 | 3,418 |
Cost of Revenue | |||||
Gross Profit | -451 | 55.2 | 2,515 | 24,994 | -270 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 10,590 | 13,647 | 14,995 | 25,582 | 16,163 |
Operating Profit | -10,308 | -12,409 | -9,855 | 4,284 | -12,745 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10,267 | -11,722 | -11,424 | -3,693 | -9,503 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10,267 | -11,723 | -11,425 | -6,237 | -9,007 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -10,195 | -11,795 | -11,425 | -6,631 | -8,756 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -10,195 | -11,795 | -11,425 | -6,631 | -8,756 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -533 | -590 | -554 | -371 | -523 |
Dividends per Share |